BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/23/2021 1:30:21 PM | Browse: 721 | Download: 1767
 |
Received |
|
2021-02-18 13:28 |
|
Peer-Review Started |
|
2021-02-18 13:33 |
|
First Decision by Editorial Office Director |
|
2021-03-16 22:25 |
|
Return for Revision |
|
2021-03-16 22:25 |
|
Revised |
|
2021-03-25 10:58 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-05-07 13:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-05-07 14:12 |
|
Articles in Press |
|
2021-05-07 14:12 |
|
Edit the Manuscript by Language Editor |
|
2021-06-25 08:13 |
|
Typeset the Manuscript |
|
2021-07-21 11:58 |
|
Publish the Manuscript Online |
|
2021-07-23 13:30 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Caecilia H C Sukowati, Korri Elvanita El-Khobar and Claudio Tiribelli |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| 2020 Grant of the Fondazione Umberto Veronesi, Milan, Italy (to Sukowati CHC) |
|
| Grant of the Regione Autonomo Friuli Venezia Giulia in Progetti Internazionali 2020 (DGR 2195 dd 20/12/2019) to the FIF |
|
|
| Corresponding Author |
Caecilia H C Sukowati, BSc, PhD, Senior Scientist, Centro Studi Fegato, Fondazione Italiana Fegato ONLUS, AREA Science Park Basovizza, SS14 km 163.5, Trieste 34149, Italy. caecilia.sukowati@fegato.it |
| Key Words |
Hepatocellular carcinoma; Programmed death-1; Programmed death ligand 1; Cancer stem cells; Cancer heterogeneity; Genetic variants |
| Core Tip |
Immune checkpoint inhibitors (ICIs), in particular the ICI against the programmed death-1/programmed death ligand 1 (PD-L1/PD-L1) axis, has been recently presented for the treatment of hepatocellular carcinoma (HCC). However, despite the success of anti-PD-1/PD-L1 in other cancers, a substantial proportion of HCC patients fails to respond. Here, we gather current information on biomarkers of anti-PD-1/PD-L1 treatment and the contribution of HCC heterogeneity and hepatic cancer stem cells. |
| Publish Date |
2021-07-23 13:30 |
| Citation |
Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 |
| URL |
https://www.wjgnet.com/1948-0210/full/v13/i7/795.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v13.i7.795 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
